PDCD1 and melanoma: Simon et al. have demonstrated that the frequency of the circulating population of cytotoxic T cells with the co-expression of PD-1 and TIGIT is a potential factor in the prediction of the success of anti-PD-1 immunotherapy in melanoma patients [90].